Tyra Biosciences, INC 10-Q quarterly reports

Tyra Biosciences, Inc. announced its Q2 2026 financial results, highlighting increased research and development spending and a widening net loss, while also noting progress in its clinical pipeline and a strong cash position extending into late 2028.

Tyra Biosciences details Q1 2026 financial results, highlighting increased R&D spending and a strong cash position, while advancing its FGFR-targeted drug candidates.

Tyra Biosciences reported increased net losses and cash burn in Q3 2025, while advancing multiple clinical programs and maintaining a cash runway through at least 2027.

Tyra Biosciences reports increased R&D spend and net loss in Q2 2025, while maintaining a strong cash position to fund operations through at least 2027.

Tyra Biosciences reports a net loss for Q1 2025, but anticipates existing funds will support operations through at least 2027 as it progresses its clinical-stage programs.

Tyra Biosciences' Q3 2024 report highlights a strengthened financial position and advancements in clinical trials for its FGFR-targeted therapies.

Tyra Biosciences reports a net loss of $18.7 million for the second quarter of 2024, alongside updates on clinical trials and pipeline development.

Tyra Biosciences reports a net loss of $18.2 million for the first quarter of 2024, while also securing $200 million through a private placement to advance its clinical programs.